CAS 1005402-19-6

Formel: C18H23N3O2

InChl: InChI=1S/C18H23N3O2/c1-14-4-2-11-21(14)12-3-13-23-16-7-5-15(6-8-16)17-9-10-18(22)20-19-17/h5-10,14H,2-4,11-13H2,1H3,(H,20,22)/t14-/m1/s1

InChI Key: XUKROCVZGZNGSI-CQSZACIVSA-N

SMILES: C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C=C3

6-[4-[3-[(2R)-2-Methyl-1-pyrrolidinyl]propoxy]phenyl]-3(2H)-pyridazinone

CAS: 1005402-19-6

Formel: C₁₈H₂₃N₃O₂

Reinheit: 98%

Farbe und Form: Solid

Molekulargewicht: 313.3941

Ref: IN-DA023P1F

Irdabisant

CAS: 1005402-19-6

Irdabisant

Formel: C₁₈H₂₃N₃O₂

Reinheit: ≥98%

Molekulargewicht: 313.39

Ref: 54-BUP12407

Irdabisant

CAS: 1005402-19-6

Irdabisant (CEP-26401) is an H3R antagonist/inverse agonist, BBB permeable, with cognition-enhancing effects for schizophrenia/cognitive research.

Formel: C₁₈H₂₃N₃O₂

Reinheit: 99.96%

Farbe und Form: White Solid

Molekulargewicht: 313.39

Ref: TM-T32191

Irdabisant

CAS: 1005402-19-6

Irdabisant is a novel small-molecule therapeutic, which functions as a histamine H3 receptor antagonist or inverse agonist. This compound is chemically synthesized and designed to target the central nervous system. The mode of action involves the selective inhibition of presynaptic H3 receptors, which are primarily responsible for modulating the release of histamine and other neurotransmitters such as acetylcholine, norepinephrine, and dopamine. By inhibiting these receptors, Irdabisant enhances neurotransmitter release, facilitating improved synaptic transmission.

Formel: C₁₈H₂₃N₃O₂

Reinheit: Min. 95%

Molekulargewicht: 313.39 g/mol

Ref: 3D-BI184163